Liraglutide (Victoza, Saxenda)
Liraglutide (recombinant DNA origin)
Liraglutide is an FDA-approved once-daily GLP-1 receptor agonist used for type 2 diabetes (Victoza) and chronic weight management (Saxenda), with demonstrated cardiovascular benefit in the LEADER trial (PMID: 27295427). The first generic liraglutide injection was FDA-approved on December 23, 2024.
Last updated: 2026-03-12
Safety Summary
GI adverse effects (nausea, vomiting, diarrhea) are dose-related, most common during initiation and dose escalation, and typically transient with continued use. Slow titration reduces GI intolerance. GI events are the most frequent cause of treatment discontinuation. A boxed warning exists for thyroid C-cell tumors observed in rodent studies (rats and mice) in a dose- and duration-dependent manner; human relevance is unknown. MTC remains a contraindication in at-risk patients. Long-term data (LEADER, real-world registries) do not show consistent increase in thyroid or pancreatic cancer in humans after adjustment for confounding and surveillance bias (LEADER neoplasm report, Diabetes Care 41(8):1663; US cohort analysis PMC8203194; Korean nationwide cohort). Weight regain is typical after discontinuation (-4.3-7.3 kg within 6-18 months) with HbA1c deterioration toward baseline. Psychiatric signals (suicidal ideation/behavior) were identified in FAERS but FDA requested removal of this warning for the GLP-1 class in January 2026.
Known Side Effects
Very common (-20-40% in Phase III trials)
Common (~10-12%)
Common (<15%)
Common (variable, <15%)
Common
Common (-¥5% in pivotal trials)
Common (-¥5%)
Common (-¥5%)
Common (-¥5%)
Common (mean increase 2-3 bpm in clinical trials)
Uncommon (~1%)
Common (-¥5%)
Rare (~0.3%)
Uncommon but more frequent than placebo (2-3x risk)
Uncommon when used alone; increased with insulin/sulfonylureas (~3% monotherapy vs ~17% with sulfonylureas)
Rare (post-marketing reports)
Rare (post-marketing reports)
Infrequent (~8% in LEAD program)
Who Should NOT Use This
Liraglutide causes thyroid C-cell tumors in rodents; MTC is a contraindication per FDA label
MEN 2 patients are at increased risk for MTC
Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported
Insufficient controlled human pregnancy data; risk-benefit assessment required.
Acute pancreatitis has been reported with GLP-1RAs. Not an absolute contraindication but use with caution.
Increased hypoglycemia risk; consider reducing insulin/secretagogue dose and increase glucose monitoring.
Liraglutide delays gastric emptying and may impact the absorption of concomitantly administered oral medications. Monitor for therapeutic effect.
Talk to Your Doctor
Before considering Liraglutide (Victoza, Saxenda), discuss it with your healthcare provider. Ask about potential interactions with your current medications, whether it is appropriate for your health conditions, and what monitoring may be needed.
Sources: [1-11]
Evidence Assessment
Liraglutide is FDA-approved for multiple indications: type 2 diabetes mellitus (Victoza, approved 2010), chronic weight management (Saxenda, approved 2014), and cardiovascular risk reduction in T2DM with established CVD. The first generic liraglutide injection was FDA-approved December 23, 2024. EMA marketing authorization exists for both Victoza and Saxenda. Also approved by TGA (Australia), Health Canada, and numerous other jurisdictions. Evidence base includes multiple large Phase III RCTs (LEAD program: LEAD-2 through LEAD-6), a landmark cardiovascular outcomes trial (LEADER, N=9,340, median 3.8 years), the SCALE obesity program (>5,000 patients), and extensive post-marketing surveillance
1Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)NCT01179048PMID 27295427
Marso SP, Daniels GH, Brown-Frandsen K, et al. - New England Journal of Medicine (2016) - Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled CVOT - 9340
Primary MACE endpoint: 13.0% liraglutide vs 14.9% placebo; HR 0.87 (95% CI 0.78-0.97; P<0.001 noninferiority, P=0.01 superiority). CV death HR 0.78 (P=0.007). All-cause death HR 0.85 (P=0.02). Median follow-up 3.8 years.
Limitations: Population limited to high-CV-risk T2DM patients; results may not generalize to lower-risk populations or non-diabetic obesity patients. Sponsored by Novo Nordisk.
2A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes)NCT01272219PMID 26132939
Pi-Sunyer X, Astrup A, Fujioka K, et al. - New England Journal of Medicine (2015) - Phase III, Randomized, Double-blind, Placebo-controlled - 3731
At 56 weeks, mean weight loss 8.4±7.3 kg with liraglutide 3.0 mg vs 2.8±6.5 kg placebo. 63.2% of liraglutide group lost -¥5% body weight vs 27.1% placebo. Reductions in visceral adipose tissue.
Limitations: High dropout rate (26.9% liraglutide, 29.6% placebo). Sponsored by Novo Nordisk.
3LEAD-2: Liraglutide Effect and Action in Diabetes -- a 26-week Phase III trialPMID 18931095
Nauck M, Frid A, Hermansen K, et al. - Diabetes Care (2009) - Phase II/III, Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled - 1091
HbA1c change: 1.8 mg = -1.0%, 1.2 mg = -1.0%, 0.6 mg = -0.7%, glimepiride = -1.0%, placebo = +0.1% (P<0.0001 vs placebo). Weight: liraglutide -1.8 to -2.8 kg vs glimepiride +1.0 kg. Hypoglycemia ~3% liraglutide vs 17% glimepiride.
Limitations: 26-week duration; primarily T2DM on background metformin.
4LEAD-3: Liraglutide monotherapy vs glimepiride -- 52-week Phase III trialPMID 18819705
Garber A, Henry R, Ratner R, et al. - Lancet (2009) - Phase III, Randomized, Double-blind, Double-dummy, Active-control - 746
HbA1c: liraglutide 1.8 mg = -1.14% (vs glimepiride difference -0.62%, P<0.0001); liraglutide 1.2 mg = -0.84%. Weight loss and lower rate of hypoglycemia vs glimepiride.
Limitations: 52-week monotherapy comparison; GI AEs were higher with liraglutide.
5LEAD-4: Liraglutide added to metformin + thiazolidinedione -- 26-week Phase III trialPMID 19289857
Zinman B, Gerich J, Buse JB, et al. - Diabetes Care (2009) - Phase III, Randomized, Double-blind, Placebo-controlled - 533
Significant improvements in HbA1c and weight vs placebo when added to metformin + TZD combination therapy.
Limitations: 26-week duration.
6LEAD-5: Liraglutide vs insulin glargine and placebo added to metformin + sulfonylurea -- 26-week trialPMID 19688338
Russell-Jones D, Vaag A, Schmitz O, et al. - Diabetologia (2009) - Phase III, Randomized, Parallel-group - 581
HbA1c: liraglutide -1.33% vs glargine -1.09% (difference -0.24%, P=0.0015) and vs placebo (P<0.0001). Greater weight loss and lower hypoglycemia with liraglutide vs glargine.
Limitations: 26-week duration; open-label component for some comparisons.
7LEAD-6: Liraglutide 1.8 mg once daily vs exenatide 10 µg twice daily -- 26-week head-to-head trialPMID 19515449
Buse JB, Rosenstock J, Sesti G, et al. - Lancet (2009) - Phase III, Randomized, Open-label, Parallel-group - 464
HbA1c: liraglutide -1.12% vs exenatide -0.79%. More patients achieved HbA1c <7% with liraglutide (54% vs 42%). Greater fasting glucose reduction. Lower nausea frequency/duration and fewer minor hypoglycemia events.
Limitations: Open-label design; 26-week duration.
8Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled TrialPMID 32139381
Garvey WT, Birkenfeld AL, Dicker D, et al. - Diabetes Care (2020) - Phase III/IV, Randomized, Controlled
Liraglutide 3.0 mg effective for weight loss in overweight/obese T2DM patients already on basal insulin.
Limitations: Sample size not extracted from available source data.
9EVIDENCE Study: Prospective 2-year post-marketing registry of liraglutide in T2DM
Not fully extracted from source - Advances in Therapy (2015) - Phase IV, Prospective, Multicenter, Observational Registry - 3152
Liraglutide generally well tolerated; GI AEs ~10.9%; hypoglycemic episodes decreased from 6.9% baseline to 4.4%; clinically meaningful improvements in HbA1c, fasting glucose, weight and patient-reported treatment satisfaction.
Limitations: Observational design; no randomized comparator.
10Liraglutide in mild to moderate Alzheimer's disease (ELAD trial)
Not fully extracted from source - Nature Medicine (2025) - Phase 2b, Randomized, Controlled
Safety demonstrated in mild-moderate AD population; some improvement in executive function. Clinical utility for neurodegeneration not yet established.
Limitations: Early-phase; did not meet primary endpoint. Sample size not extracted.
11Neoplasms Reported With Liraglutide or Placebo in the LEADER Trial
Not fully extracted from source - Diabetes Care (2018) - Post-hoc analysis of LEADER CVOT - 9340
No consistent, clinically meaningful increase in thyroid cancer, pancreatic cancer, or MTC with liraglutide after adjustment for confounding and surveillance bias.
Limitations: Post-hoc analysis; limited statistical power for rare cancer events.